Opioid management for symptom relief in serious illness is a core aspect of palliative care (PC) practice, with additional complexities to consider when prescribing in the outpatient setting. Safe and timely access to necessary opioids for patients depends on clinicians writing accurate prescriptions, navigating health care insurance(s), planning for potential medication shortages, and close collaboration with outpatient pharmacies. Access should be supported by, and balanced with, appropriate risk-mitigation strategies, including regular clinical assessments, thoughtful medication selection to minimize adverse effects, and ongoing education for patients and clinicians. This article—written by an interprofessional team of PC-trained physicians, nurse practitioners, pharmacists, clinical practice nurses, and social workers—summarizes ten practical tips for navigating outpatient opioid prescribing.
PaiceJA, BohlkeK, BartonD, et al.Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol, 2023; 41(4):914–930.
2.
HuiD, BohlkeK, BaoT, et al.Management of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol, 2021; 39(12):1389–1411.
3.
NiciL, MammenMJ, CharbekE, et al.Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med, 2020; 201(9):e56–e69.
4.
Di PaloKE, FederS, BaggenstosYT, et al.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Palliative pharmacotherapy for cardiovascular disease: A scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes, 2024; 17(8):e000131; doi: 10.1161/HCQ.0000000000000131
5.
ThompsonJ. The WHO guidelines: The new and the old. Curr Opin Support Palliat Care, 2024; 18(4):169–174.
6.
SwarmRA, YoungwerthJM, AgneJL, et al.Adult cancer pain, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2025; 23(7):e250032; doi: 10.6004/jnccn.2025.0032
7.
Fitzgerald JonesK, KhodyakovD, ArnoldR, et al.Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder. JAMA Oncol, 2022; 8(8):1107–1114.
8.
RodinR, AfezolliD, PellegA, et al.The silent opioid crisis: Finding a balance between combating abuse and increasing access for seriously ill patients. NEJM Catal, 2025; 6; doi: 10.1056/CAT.24.0380
RodinRA, SmithCB. The challenge of opioids in cancer care: Balancing equity, safety, and access. Ann Palliat Med, 2024; 13(5):1301–1306.
11.
BrennanT, CreagerR, PolinskiJM. Pharmacy benefit management of opioid prescribing: The role of employers and insurers. Health Affairs Forefront Blog, 2017; doi: 10.1377/forefront.20170921.062092
12.
BaoY, ZhangH, HartungDM, et al.Medicare part D coverage restrictions and patient cost-sharing for opioids commonly used for cancer pain, 2015–2021. JCO Oncol Pract, 2022; 18(10):e1574–e1586.
13.
DavisCS, LiebermanAJ. Laws limiting prescribing and dispensing of opioids in the United States, 1989–2019. Addiction, 2021; 116(7):1817–1827.
14.
PaiceJA. Risk assessment and monitoring of patients with cancer receiving opioid therapy. Oncologist, 2019; 24(10):1294–1298.
15.
HeungY, ClarkM, TschanzJ, et al.Opioid prescription denials by community pharmacies for cancer-related pain: A case series. J Pain Symptom Manage, 2023; 66(3):e431–e435.
16.
FisherL, AndryB, CarrS, et al.Factors impacting patient access to prescription opioids in serious illnesses community pharmacy perspectives. J Pain Symptom Manage, 2024; 67(5):e684.
CarvalhoAS, Martins PereiraS, JácomoA, et al.Ethical decision making in pain management: A conceptual framework. J Pain Res, 2018; 11:967–976.
19.
SkarfL, SchaeferK, NarangS, et al.“The dog ate my methadone”: Challenges treating patients with advanced illness, pain, and addiction (P3). J Pain Symptom Manage, 2012; 43(2):315–316.
20.
EnzingerAC, GhoshK, KeatingNL, et al.Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol, 2023; 41(14):2511–2522.
21.
JohnsonKS, BullockK, SmithCB, et al.Evaluation of reporting of race and ethnicity in hospice and palliative care research. J Palliat Med, 2025; 28(6):708–715; doi: 10.1089/jpm.2023.0694
22.
DowellD, RaganKR, JonesCM, et al.CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep, 2022; 71(3):1–95.
23.
DowellD, RaganKR, JonesCM, et al.Prescribing opioids for pain—The new CDC clinical practice guideline. N Engl J Med, 2022; 387(22):2011–2013.
24.
DavisMP, DigwoodG, MehtaZ, et al.Tapering opioids: A comprehensive qualitative review. Ann Palliat Med, 2020; 9(2):586–610.
25.
McAuliffe StaehlerTM, PalombiLC. Beneficial opioid management strategies: A review of the evidence for the use of opioid treatment agreements. Subst Abus, 2020; 41(2):208–215.
26.
ArthurJ, ChildersJ, Del FabbroE. Should urine drug screen be done universally or selectively in palliative care patients on opioids? J Pain Symptom Manage, 2023; 66(6):e687–e692.
27.
GudinJ, FudinJ. A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther, 2020; 9(1):41–54.
28.
NealeKJ, WeimerMB, DavisMP, et al.Top ten tips palliative care clinicians should know about buprenorphine. J Palliat Med, 2023; 26(1):120–130.
29.
ChwistekM, SherryD, KinczewskiL, et al.Should buprenorphine be considered a first-line opioid for the treatment of moderate to severe cancer pain? J Pain Symptom Manage, 2023; 66(5):e638–e643.
CaseAA, DavisMP, ChwistekM, et al.Buprenorphine for cancer pain—The safest opioid, and patients with cancer cannot get it. JAMA Oncol, 2025; 11(8):825–826.
BullsHW, BellLF, OrrisSR, et al.Exemptions to state laws regulating opioid prescribing for patients with cancer‐related pain: A summary. Cancer, 2021; 127(17):3137–3144.
36.
Goddard-EckrichD, GrealisK, El-BasselN, et al.Development of a brief stigma and perceptions questionnaire for pharmacists: An exploratory factor analysis approach in New York state counties enrolled in the healing communities study. J Subst Use Addict Treat, 2025; 169:209566.
CraneWBP, PageA, NadparaPA, et al.Effect of community pharmacist-provided patient education of partial fill availability for acute opioid prescriptions. J Am Pharm Assoc (2003), 2022; 62(4S):S22–S28.
44.
SalzbrennerSG, LydiattM, HeldingB, et al.Influence of prior authorization requirements on provider clinical decision-making. Am J Manag Care, 2023; 29(7):331–337.
45.
GuptaR, FeinJ, NewhouseJP, et al.Comparison of prior authorization across insurers: Cross sectional evidence from Medicare Advantage. BMJ, 2024; 384:e077797.
46.
QuesenberryPJ, NimarkoK. Reducing the burden of medication prior authorizations. Fam Pract Manag, 2024; 31(5):22–27.
RosaWE, PettusKI, De LimaL, et al.Top ten tips palliative care clinicians should know about evidence-based advocacy. J Palliat Med, 2021; 24(8):1240–1245.
